{"id":"azd-1222","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"50-60","effect":"Fatigue"},{"rate":"50-60","effect":"Headache"},{"rate":"40-50","effect":"Myalgia"},{"rate":"20-30","effect":"Fever"},{"rate":"20-30","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL603038","moleculeType":"Small molecule","molecularWeight":"394.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD1222 uses a replication-deficient chimpanzee adenovirus vector to carry the gene encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, generating antibodies and T-cell immunity against the spike protein. The vaccine does not contain the live virus and cannot cause COVID-19 infection.","oneSentence":"AZD1222 is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:16.828Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT05126992","phase":"","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-02-18","conditions":"COVID-19, Vaccine Adverse Events of Special Interest","enrollment":5321930},{"nctId":"NCT05057897","phase":"PHASE4","title":"A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-31","conditions":"COVID-19, SARS-CoV-2","enrollment":34},{"nctId":"NCT05940194","phase":"PHASE2","title":"NDV-HXP-S Vaccine Clinical Trial (COVIVAC)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2021-08-11","conditions":"COVID-19","enrollment":374},{"nctId":"NCT04973449","phase":"PHASE2, PHASE3","title":"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-06-27","conditions":"COVID-19, SARS-CoV-2","enrollment":2843},{"nctId":"NCT05054621","phase":"PHASE2","title":"Immunogenicity of COVID-19 Vaccine on Heterologous Schedule","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-09-15","conditions":"Covid-19, Vaccine, Immunogenicity","enrollment":100},{"nctId":"NCT04568031","phase":"PHASE1, PHASE2","title":"Study of AZD1222 for the Prevention of COVID-19 in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-23","conditions":"COVID-19","enrollment":256},{"nctId":"NCT04516746","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-28","conditions":"COVID-19, SARS-CoV-2","enrollment":32450},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT05198596","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-30","conditions":"COVID-19 Vaccine","enrollment":250},{"nctId":"NCT05426343","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-09","conditions":"COVID-19 Vaccine","enrollment":200},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05007275","phase":"PHASE1","title":"A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-10-10","conditions":"Covid19, SARS-CoV-2 Infection","enrollment":28},{"nctId":"NCT04914832","phase":"PHASE4","title":"Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death","status":"COMPLETED","sponsor":"Shabir Madhi","startDate":"2021-08-30","conditions":"COVID-19, Pneumonia, Viral","enrollment":75012},{"nctId":"NCT05442684","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine","status":"WITHDRAWN","sponsor":"CanSino Biologics Inc.","startDate":"2022-11-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05715944","phase":"PHASE3","title":"Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2","status":"COMPLETED","sponsor":"Botswana Harvard AIDS Institute Partnership","startDate":"2021-09-15","conditions":"COVID-19","enrollment":10888},{"nctId":"NCT05076227","phase":"","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","status":"COMPLETED","sponsor":"Serge Thal","startDate":"2021-01-30","conditions":"SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity","enrollment":1206},{"nctId":"NCT04760730","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-07-13","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05011526","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-10-08","conditions":"Covid19 Vaccine","enrollment":1030},{"nctId":"NCT05049226","phase":"PHASE2","title":"Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-09-24","conditions":"COVID-19 Infection, COVID-19 VACCINE","enrollment":1250},{"nctId":"NCT04877743","phase":"","title":"Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":27},{"nctId":"NCT04684446","phase":"PHASE1, PHASE2","title":"Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-09-15","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04686773","phase":"PHASE2","title":"Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-03-05","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT04824651","phase":"","title":"Covid-19 Vaccine Cohort in Specific Populations","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-03-25","conditions":"Immune Deficiency","enrollment":6920},{"nctId":"NCT05133609","phase":"PHASE1, PHASE2","title":"COVID-19 VACCINE SAFETY AND EFFECTIVENESS","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2021-01-15","conditions":"SARS-CoV-2 Infection","enrollment":550},{"nctId":"NCT04540393","phase":"PHASE3","title":"AZD1222 Vaccine for the Prevention of COVID-19","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-09-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04988048","phase":"PHASE2","title":"Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina","status":"UNKNOWN","sponsor":"Ministry of Public Health, Argentina","startDate":"2021-08-03","conditions":"COVID-19 VACCINE, Covid19","enrollment":1760},{"nctId":"NCT05059106","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2021-06-01","conditions":"SARS-CoV-2","enrollment":29637},{"nctId":"NCT04794946","phase":"NA","title":"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2021-03-19","conditions":"Liver Cirrhosis","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[{"count":93,"reaction":"DRUG INEFFECTIVE"},{"count":92,"reaction":"OFF LABEL USE"},{"count":91,"reaction":"FATIGUE"},{"count":90,"reaction":"COVID-19"},{"count":79,"reaction":"CONDITION AGGRAVATED"},{"count":79,"reaction":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION"},{"count":78,"reaction":"COLITIS ULCERATIVE"},{"count":78,"reaction":"HEADACHE"},{"count":78,"reaction":"PAIN"},{"count":77,"reaction":"FREQUENT BOWEL MOVEMENTS"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaxzevria®","Covishield®","ChadOx1 nCoV-19","ChAdOx1 nCoV-19"],"phase":"phase_3","status":"active","brandName":"AZD 1222","genericName":"AZD 1222","companyName":"University Medicine Greifswald","companyId":"university-medicine-greifswald","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD1222 is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19. Used for COVID-19 prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}